Skip to main content

Merck KGaA

corporate_fare Company Profile

Merck KGaA

MKGAF·OTC·Life Sciences·CIK 0001764133

Merck KGaA is a science and technology company operating in Europe, North America, Latin America, the Middle East and Africa, and the Asia Pacific. It reports three business segments. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector, including reagents, consumables, devices, instruments, software, and services for research, production, and testing, lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. It also provides traditional and novel therapies such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing, plus contract development, manufacturing and testing services supporting customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals in oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; delivery equipment for handling specialty chemicals and gases for semiconductor manufacturing; technologies for modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. Merck KGaA has an in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor, and a strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Merck KGaA (OTC:MKGAF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for MKGAF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-11, rated 7/10.

Recent high-impact activity:

  • FDA Approves Once-Daily Oral Therapy for Rare Joint Tumor

Short Interest & Short Volume

FINRA reported short interest of 664,956 shares in MKGAF as of the October 30, 2026 settlement, a 3.4% increase from the prior period. On November 20, 2026, 58.8% of MKGAF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)664,956 shares as of October 30, 2026
Change vs prior period▲ 3.4%
Daily short volume (FINRA facilities)58.8% of 119 shares on November 20, 2026
5-day average short volume80.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$155.5 -4.86% today
52-week range · as of 2026-11-11 $116.68 – $175.56
Market cap
$67.61B
Volume
119 (0.4× avg)
3-mo avg 294.3
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MKGAF - Latest Insights

MKGAF
Nov 11, 2026, 7:46 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $166.62
Real-time Price: $155.50 info
Change: -$11.12 (-7%) info
Market Cap: $67.608B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets